Doctor Daniel Berger

Bio: Doctor Daniel Berger


Dr. Daniel S. Berger is a leading HIV specialist in the U.S. He is Associate Professor of Medicine at the University of Illinois and founder of Northstar Medical Center, the largest private HIV-treatment and research center in Greater Chicago. Dr. Berger is well known nationally and internationally among researchers and individuals engaged in HIV drug development. He has published more than 70 articles and abstracts in peer-reviewed medical journals and international conferences on antiretroviral therapy and other HIV-related treatment. Dr. Berger has conducted more than 200 HIV-related clinical research trials and published extensively in medical journals including the Lancet and the New England Journal of Medicine. In 1992, he conducted the world’s first study of combination therapy for HIV infection, presenting his findings at World AIDS in Amsterdam later that year. This research became a stepping-stone to the AIDS drug cocktail that followed 3 years later. During the years 2005-2010, antiretroviral therapy for HIV disease experienced a revolution in therapeutics. Berger was heavily involved as principal investigator of these agents and co-authored several resultant iconic publications of these studies. Among his book publications, he contributed to "HIV – The First Year, An Essential Guide for the Newly Diagnosed" (Marlow & Company) and "Nutritional Aspects of HIV Disease" (Oxford Univ Press). Dr. Berger lectures nationally to physicians, educating them on the latest HIV-research studies. Dr. Berger has served on numerous boards and committees including the Medical Issues Committee for the Illinois AIDS Drug Assistance Program and the AIDS Foundation of Chicago. In 2006, Berger was honored by Test Positive Aware Network with the Charles E Clifton Leadership Award; in 2016 the Chicago Reader named Dr. Berger as #1 Practitioner of the Year. In 2021, Dr. Daniel Berger was the recipient of the Visual AIDS Vanguard Award (VAVA) in New York for his exceptional work as an HIV specialist who has made essential contributions to HIV and AIDS medical treatments, as well as his passion for art and the legacy of art AIDS activism as a collector, curator, archivist, and philanthropist.

As an active patron of the arts, in 2010, Dr. Berger founded Iceberg Projects, an alternative exhibition space in Chicago. In 2015, Dr. Berger acquired the archives of Art+Positive, an important affinity group of ACT UP New York and co-curated the first exhibition of the archives. To disseminate the ephemera within the archive he co- published Militant Eroticism: The Art+Positive Archives (Sternberg Press, Berlin). Additionally, Dr. Berger curated Chicago’s first David Wojnarowicz solo show and subsequently published David Wojnarowicz: Flesh of My Flesh (SPD, Berkeley, CA). To support young artists, Dr. Berger founded a Scholarship at the School of the Art Institute of Chicago's MFA program: The Daniel Berger Barbara DeGenevieve Scholorship is awarded each year to a student whose work explores the boundaries of identity, an impassioned theme of the late Barbara DeGenevieve. Beginning in 2016, Dr. Berger was listed by Newcity’s The Art 50 as one of the top 50 most influential individuals in Chicago's Art Community and recently was added to Newcity’s Art Hall of Fame. He is a member of the Board of Governors for the Art Institute of Chicago, member of Collections and Acquisitions Committee of the Museum of Contemporary Art of Chicago, member of the Board of Advisors of the Block Museum of Northwestern University and the Board of Trustees of the Leslie-Lohman Museum of Art in NY. When not on a board or practicing medicine, he shares his time with his dog Nero and his life partner Scott.

Chicago Aids Doctor Daniel Berger founder of Northstar Healthcare HIV Medical Center in Chicago

Dr. Berger's Wikipedia Page

Selected Bibliography from Peer Review Journals and Conferences:

Raltegravir Versus Efavirenz Regimens in Treatment-Naïve HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analysis. Jeffrey L. Lennox, Edwin DeJesus, Daniel S. Berger, Adriano Lazzarin, Richard B. Pollard, Jose Valdez Ramalho Madruga, Jing Zhao, Hong Wan, Christopher L Gilbert, Hedy Teppler, Anthony J. Rodgers, Richard J.O. Barnard, Michael D. Miller, Mark J. DiNubile, Bach-Yen Nguyen, Randi Leavitt, Peter Sklar for the STARTMRK Investigators. J Acquir Immune Defic Syndr. 2010. doi: 10.1097/QAI.0b013e3181da1287

Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial. Andrew R. Zolopa, Daniel S. Berger, Harry Lampiris, Lijie Zhong, Steven L. Chuck, Jeffrey V. Enejosa, Brian P. Kearney, and Andrew Cheng. JID 2010;201:814-22.

Safety and Efficacy of Raltegravir-based versus Efavirenz-based Combination Therapy in Treatment-Naïve Patients with HIV-1Infection: A Multicentre, Double-Blind Randomised Controlled Tria: Jeffrey L Lennox, Edwin DeHesus, Adriano Lazzarin, Richard Pllard, Jose Madruga, Daniel S. Berger, Jing Zhao, Xia Xu, Angela Williams-Diaz, Anthony J Rodgers Michael Miller, Mark DiNubile, Bach-Yen Nguyen, Rahndi Leavitt, Peter Sklar, for the STARTMRK investigators. The Lancet, Earlly Online Publication, 3, August 2009. doi:10,1016/S0140-6736(09)60918-1.

Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir Based vs Efavirenz-Based Combination Therapy: 48-0Week Data. E DeJesus, A Lazzarin, J Lennox, D. Berger R. Pollard, J Madruga, J Zhao, A Godgers, B Nguyen, R Leavitt, P Sklar. 49th ICAAC San Francisco, CA Sept 12-15 2009; abstr H-1571

Raltegravir Demonstrates Durable Efficacy Through 96 Weeks: Results from STARTMRK, A Phase III Study of Raltegravir-based vs Efavirenz-based Therapy in Treatment-Naïve HIV+ Patients. J lennox, E DeJesus, A Lazzarin, , D. Berger R. Pollard, J Madruga, J Zhao, A Godgers, B Nguyen, R Leavitt, P Sklar. 49th ICAAC San Francisco, CA Sept 12-15 2009; abstr H-924b

Long-term Safety and Effects of Tesamorelin, a Growth hormone-releasing Factor Analogue, in HIV Patients with Abdominal Fat Acumulation.Julian Falutz, Soraya Allas, Jean-Claude Mamputu, Diane Potvin, Donald Kotler, Michael Somero, Daniel Berger, Stephen Brown, Gary Richmond, Jeffrey Fessel, Ralph Turner and Steven Grinspoon. AIDS 2008;22:1719-28

B Young, K Smith, P Patel, M Markowitz, D Berger, P Wannamaker, L Yau, C Vavro. Characterization of Virologic Failure Over 96 Weeks by Drug Resistance and Antiviral Responose in ART Naïve Patients Receiving Abacavir/Lamivudine or Tenofovir/Emtricitabine Each with Lopinavir/Ritonavir QD in the HEAT Study. 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington DC, Oct 25-28, 2008.

abstr# H1233.

Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. Julian Falutz, Soraya Allas, Koenraad Blot, Diane Potvin, Donald Kotler, Michael Somero, Daniel Berger, Stephen Brown, Gary Richmond, Jeffrey Fessel, Ralph Turner and Steven Grinspoon. New Engl J Med 2007;357:2359-70.

Influence of Baseline Factors on Virologic Response to Darunavir/Ritonavir (DRV/r) vs Lopinavir/r (LPV/r): Week 48 Outcome in TITAN. Berger DS, Northland R, Scribner A, De Paepe E, De Meyer S, Moriarty D, Spinoza-Guzman S. 11th European AIDS Conference, Madrid, Spain, 24–27 October 2007.

A Randomized, Controlled Phase III Trial Compariing 48-week Efficacy and Safety of Darunavir/Ritonavir (DRV/r) with Lopinavir/Ritonavir (LPV/r) in treatment experienced patients: TITAN. JoseValdez-Madruga, Daniel Berger, Marilyn McMurchie, Fredy Suter, Denes Banhegyi, Dorece Norris, Eric Lefebvre, Tony Vangeneugden, Marie-Pierre de Bethune, Frank Tomaka, Martine De Pauw , Sabrina Spinosa-Guzman. The Lancet 2007; 370:49-58

Week 24 Efficacy and Safety of TMC114/ritonavir in treatment-experienced HIV Patients: R Haubrich, D. Berger, P Chilade, A Colson, M Conant, J Gallant, R Gulick, J Nadler, G Pierone, M Saag, P Shalit, B van Baelen M de Bethune, A Koest er, W Parys, V Sekar, E Lefebvre on behalf of Power 2 study group AIDS 2007, 21:F11-F18.

Efficacy and Safety of TMC125 in Patients with Highly Resistant HIV-1: Primary 24-week Analysis of trial TMC125-C223. The TMC 125-C223 Writing Group: Jeffrey Nadler, Calvin Cohen, Gary Blick, Dushyantha Jayaweera, Charles Hicks, Peter Shalit, Melanie Thompson, Daniel Berger, Stephen Smith, Shannon Schrader, Douglas Ward, Richard Greenberg, Paul Cimoch, Corklin Steinhart, Peter Ruane, Anthony Mills, , Monika Peeters, Kathy Iveson, Ellen Voorspoers Brian Woodfall. AIDS 21(6): F1-F10, March 2007.

Once-daily abacavir/lamivudine (ABC/3TC) and boosted Atazanavir (ATV/RTV) in antiretroviral-naïve HIV-1 infected subjects: 48-week results from COL102060 (SHARE); Elion R, Dehesus E, Sension M, Berger D, Towner W, Richmond G, Yau L, Ha B, COL102060 Study Team. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sidney, Australia, 22-25 July 2007.

The HIV integrase inhibitor GS-9137 has potent antiretroviral activity in treatment-experienced patients Zolopa AR, Mullen M, Berger D, Ruane P, Hawkins T, Zhong L, Steven Chuck, Jeffrey Enejosa, Brian Kearney, Andrew Cheng. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, 2007. Abstract 143LB.

Effects of TH9507, a Growth Hormone Releasing Factor (GRF) Analog, on HIV-associated abdominal fat accumulation: A Multicenter, Double-blind Placebo-controlled Trial with 412 Randomized Patients. Julian Falutz, Soraya Allas, Diane Potvin, Donald Kotler, Michael Somero, Daniel Berger, Stephen Brown, Gary Richmond, Jeffrey Fessel and Steve Grinspoon. 14th Conference on Retroviruses and Opportunistic Infections (CROI) Los Angeles, Feb 27, 2007. Abstr 45-LB (Late-Breaker)

Antiviral activity, Pharmacokinetics and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naïve and Treatment-Experienced Patients. Edwin DeJesus, Daniel Berger, Martin Markowitz, Calvin Cohen, Trevor Hawkins, Peter Ruane, Richard Elion, Charles Farthing, Lijie Zhong, Andrew K Cheng, Damian McColl, Brian P. Kearney for the 183-0101 Study Team. J Acqu Immune Defic Syndr 2006;43:1-5.

TMC114/r in 3-Class-Experienced Patients: 24-we Primary Safety Analysis of the Power 2 study (C202).Berger DS, Bellos N, Farthing C, Stryker R, Colson A, Pierone G, Lefebvre E, Cefalone M, Koester A, Van Baelen K, De Pauw M. 45st Interscience Conference on Antimicrobial Agents and Chemotherapy. Dec 16-19, 2005, Wash DC abst H-1094.

Efficacy and safety of once-daily abacavir/lamivudine fixed-dose combination (ABC/3TC) + efavirenz (EFV): ESS30009 planned 48 week analysis. JE Gallant, AE Rodriguez, W Weinberg, B Young, D Berger, JL Lim. Liao Q, Ross L, Johnson J, Shaefer MSAmerican College of Clinical Pharmacy Annual Meeting (October 23 - 26, 2005), San Francisco, CA (encore presentation).